MyFinsight

HomeBlogAboutContact

MyFinsight

Making company financials insightful for everyone

Quick Links

  • About
  • Blog
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

For the quarter ending 2026-03-31, ENSC has $2,167,803 in assets. $2,836,815 in debts. $745,482 in cash and cash equivalents.

Balance Sheets Overview

Current Ratio
70.80%
Quick Ratio
70.80%
Cash Ratio
26.28%
Debt to Asset Ratio
130.86%
Unit: Dollar
Assets Breakdown
    • Cash and cash equivalents
    • Property and equipment, net
    • Other assets
Liabilities Breakdown
    • Accumulated deficit
    • Additional paid-in capital
    • Accounts payable
    • Others

Balance Sheets
2026-03-31
2025-12-31
2025-09-30
2025-06-30
Cash and cash equivalents
745,482 4,310,354 1,673,218 2,211,575
Unbilled receivable
-420,345 4,411 1,204,979
Prepaid expenses and other current assets
1,263,058 2,511,769 1,250,641 1,865,041
Total current assets
2,008,540 7,242,468 2,928,270 5,281,595
Property and equipment, net
117,596 124,129 123,643 -
Other assets
41,667 85,882 127,551 292,860
Total assets
2,167,803 7,452,479 3,179,464 5,574,455
Other long-term liabilities
--35 1,033
Total long-term liabilities
--35 1,033
Accounts payable
1,610,186 3,267,610 463,458 1,042,832
Accrued expenses and other liabilities
980,780 993,411 1,453,555 1,045,657
Notes payable and accrued interest
245,849 306,708 387,702 424,521
Total current liabilities
2,836,815 4,567,729 2,304,715 2,513,010
Total liabilities
2,836,815 4,567,729 2,304,750 2,514,043
Common stock, 0.0001 par value, 250,000,000 shares authorized at march 31, 2026 and december 31, 2025 9,277,825 and 4,574,983 shares issued at march 31, 2026 and december 31, 2025, respectively 9,277,819 and 4,574,977 shares outstanding at march 31, 2026 and december 31, 2025, respectively
929 459 320 241
Additional paid-in capital
142,935,443 142,933,260 138,155,394 136,612,043
Accumulated deficit
-143,276,414 -139,719,999 -136,952,351 -133,223,223
Total ensysce biosciences, inc. stockholders equity (deficit)
-340,042 3,213,720 1,203,363 3,389,061
Noncontrolling interests in stockholders equity (deficit)
-328,970 -328,970 -328,649 -328,649
Total stockholders equity (deficit)
-669,012 2,884,750 874,714 3,060,412
Total liabilities and stockholders equity (deficit)
2,167,803 7,452,479 3,179,464 5,574,455
Unit: Dollar. Numbers labeled with * are estimated quarterly values.

Time Plot

Show the time plot by selecting a row from the table.

Balance Sheets

Prepaid expenses andother current assets$1,263,058 Cash and cashequivalents$745,482 Total current assets$2,008,540 Property and equipment,net$117,596 Other assets$41,667 Accumulated deficit-$143,276,414 Total assets$2,167,803 Total ensyscebiosciences, inc....-$340,042 Noncontrolling interests instockholders equity...-$328,970 Additional paid-in capital$142,935,443 Common stock, 0.0001par value,...$929 Total liabilities andstockholders equity...$2,167,803 Total stockholdersequity (deficit)-$669,012 Total liabilities$2,836,815 Total currentliabilities$2,836,815 Accounts payable$1,610,186 Accrued expenses andother liabilities$980,780 Notes payable andaccrued interest$245,849

Ensysce Biosciences, Inc. (ENSC)

Ensysce Biosciences, Inc. (ENSC)